PL425356A1 - Application of α,β dihydro xanthohumol - Google Patents

Application of α,β dihydro xanthohumol

Info

Publication number
PL425356A1
PL425356A1 PL42535618A PL42535618A PL425356A1 PL 425356 A1 PL425356 A1 PL 425356A1 PL 42535618 A PL42535618 A PL 42535618A PL 42535618 A PL42535618 A PL 42535618A PL 425356 A1 PL425356 A1 PL 425356A1
Authority
PL
Poland
Prior art keywords
xanthohumol
dihydro
application
dihydroxanthohumol
chemoprevention
Prior art date
Application number
PL42535618A
Other languages
Polish (pl)
Inventor
Tomasz Tronina
Jarosław Popłoński
Agnieszka Bartmańska
Sandra Sordon
Magdalena Milczarek
Beata Filip-Psurska
Joanna Wietrzyk
Ewa Huszcza
Original Assignee
Wrocław University Of Environmental And Life Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wrocław University Of Environmental And Life Sciences filed Critical Wrocław University Of Environmental And Life Sciences
Priority to PL42535618A priority Critical patent/PL425356A1/en
Publication of PL425356A1 publication Critical patent/PL425356A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Zgłoszenie dotyczy zastosowania ?,ß-dihydroksantohumolu o wzorze 1 w preparacie wykorzystywanym w chemoprewencji chorób nowotworowych i lekach wykorzystywanych w terapii leczenia raka piersi nowotworów estrogenozależnych.The application relates to the use of α, β-dihydroxanthohumol of the formula I in a preparation used in the chemoprevention of neoplastic diseases and drugs used in the treatment of breast cancer in estrogen-dependent neoplasms.

PL42535618A 2018-04-25 2018-04-25 Application of α,β dihydro xanthohumol PL425356A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL42535618A PL425356A1 (en) 2018-04-25 2018-04-25 Application of α,β dihydro xanthohumol

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL42535618A PL425356A1 (en) 2018-04-25 2018-04-25 Application of α,β dihydro xanthohumol

Publications (1)

Publication Number Publication Date
PL425356A1 true PL425356A1 (en) 2019-11-04

Family

ID=68501191

Family Applications (1)

Application Number Title Priority Date Filing Date
PL42535618A PL425356A1 (en) 2018-04-25 2018-04-25 Application of α,β dihydro xanthohumol

Country Status (1)

Country Link
PL (1) PL425356A1 (en)

Similar Documents

Publication Publication Date Title
CY1123666T1 (en) MEDICINAL COMPOUNDS
ECSP20020410A (en) ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES OF THE SAME
PE20191474A1 (en) AMINO-TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
CL2016002516A1 (en) "Substituted spirocycle derived compounds, atx inhibitors; pharmaceutical composition comprising them; and its use in the treatment of cancer, inflammations, neuropathic pain, fibrotic diseases, thrombosis, among others ”. pct
EA201891049A1 (en) ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS MNK1 AND MNK2
CO2018004776A2 (en) Therapeutic compositions for the treatment of human immunodeficiency virus
CO2019009722A2 (en) Therapeutic dendrimers
PH12016502352A1 (en) Pharmaceutical composition
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
MX2019015211A (en) Compounds for treating tnbc.
EA201892834A1 (en) COMBINED CHEMOTHERAPY
DOP2016000254A (en) PHARMECEUTIC FORMULATIONS OF PAN-RAF QUINASE INHIBITOR, PROCEDURES FOR THEIR PREPARATION, AND METHODS OF USE.
AR112102A1 (en) TINOSTAMUSTINE FOR USE IN THE TREATMENT OF OVARY CANCER
TW201613578A (en) Pharmaceutical combinations
ECSP18060875A (en) DERIVATIVES OF 8-AMINO-2-OXO-1,3-DIAZA-SPIRO- [4.5] -DECANO
CY1119793T1 (en) PARKINSON'S CONSTANT DOSAGE COMBINATION TREATMENT
ECSP16086247A (en) (S) -PIRLINDOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE
MX2022014792A (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same.
AR103118A1 (en) ANAMORELINE-BASED MEDICAL TREATMENTS
CL2020000270A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor.
PL425356A1 (en) Application of α,β dihydro xanthohumol
BR112019017314A2 (en) pharmaceutical compositions for combination therapy
CL2019003288A1 (en) A pharmaceutical combination for the treatment of cancer.
CL2022002064A1 (en) A pharmaceutical combination for the treatment of cancer
CY1122561T1 (en) BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS